Association Between Plasma Monocyte Chemoattractant Protein-1 Concentration and Cardiovascular Disease Mortality in Middle-Aged Diabetic and Nondiabetic Individuals by Piemonti, Lorenzo et al.
Association Between Plasma Monocyte
Chemoattractant Protein-1 Concentration
and Cardiovascular Disease Mortality in
Middle-Aged Diabetic and Nondiabetic
Individuals
LORENZO PIEMONTI, MD
1
GILIOLA CALORI, MD
2
GUIDO LATTUADA, PHD
3
ALESSIA MERCALLI, PHD
1
FRANCESCA RAGOGNA, PHD
3
MARIA PAOLA GARANCINI, MD
4
GIACOMO RUOTOLO, MD
2,5
LIVIO LUZI, MD
1,3,6
GIANLUCA PERSEGHIN, MD
1,3,6
OBJECTIVE — Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a chemokine in-
volvedintothepathogenesisofatherosclerosisandhasprognosticvalueintheacuteandchronic
phases in patients with acute coronary syndromes.
RESEARCH DESIGN AND METHODS — MCP-1/CCL2 concentration was measured
in plasma fractions of 363 middle-aged overweight/obese individuals (aged 61  12 years, BMI
30.1  6.6 kg/m
2, 15% with type 2 diabetes, and 12% with impaired glucose tolerance) of a
population survey carried out in 1990–1991 in Lombardy, Italy (Cremona Study), and cardio-
vascular disease (CVD) mortality was assessed in 2006 through Regional Health Registry ﬁles.
RESULTS — AtbaselineMCP-1/CCL2wasincreasedinindividualswithtype2diabetes(P
0.05)andshowedsigniﬁcantcorrelationswithbiochemicalriskmarkersofatherosclerosis.After
15 years, among the 363 subjects, there were 82 deaths due to CVD. In univariate analysis age,
sex, fasting glucose and insulin, ﬁbrinogen, glucose tolerance status, smoking habit, and MCP-
1/CCL2wereassociatedwithCVDmortality.Age,sex,fastingserumglucose,MCP-1/CCL2,and
smokinghabitmaintainedanindependentassociationwithCVDmortalityinmultipleregression
analysis.Inasubgroupof113subjectsinwhomdataforC-reactiveprotein(CRP)wereavailable,
its level was not predictive of CVD mortality.
CONCLUSIONS — In middle-aged overweight/obese individuals MCP-1/CCL2 was inde-
pendently associated with CVD mortality. Further studies will be necessary to establish its role
as a surrogate biomarker and as a potential therapeutic target.
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A
therosclerosis is the result of an ex-
cessive proliferative and inﬂamma-
tory response that includes smooth
muscle cell migration and proliferation,
inﬂammatory cell inﬁltration, neovascu-
larization,productionofextracellularma-
trix, and the accumulation of lipids (1).
Monocyte chemoattractant protein-1
(MCP-1/CCL2), a member of the CC che-
mokine family, is involved in most of
these processes (2). In culture systems,
oxidized LDL (3) and shear stress (4) up-
regulated MCP-1/CCL2 synthesis in hu-
man endothelial cells. In animal models,
the role of MCP-1/CCL2 appears to be
more evident; MCP-1/CCL2 knockout
mice placed in an LDL receptor–deﬁcient
background showed an 80% reduction of
atherosclerotic plaque and a reduction in
the number of macrophages in the aortic
walls (5), and similar results were ob-
tained in mice deﬁcient in the MCP-1/
CCL2 receptor (CCR2) crossed with
apolipoprotein E–deﬁcient mice (6).
If in animal models the role of MCP-
1/CCL2inatherosclerosisappearedclear,
its role in vivo in humans remains un-
known. MCP-1/CCL2 levels were found
to be increased in aging (7), hypertension
(8), hypercholesterolemia (9), and renal
failure(10)andtohaveaprognosticvalue
in the acute and chronic phases in pa-
tients with acute coronary syndromes
(11,12). We were the ﬁrst to report in-
creased MCP-1/CCL2 plasma levels in di-
abetic individuals (13). In that study we
found that in 207 women selected from a
population survey carried out in 1990–
1991 in Lombardy, Italy (Cremona
Study), because a properly stored spared
fraction of plasma was available, baseline
MCP-1/CCL2 correlated with risk mark-
ers of cardiovascular disease (CVD). In
addition, we reported that in univariate
analysis MCP-1/CCL2 was signiﬁcantly
associated with CVD mortality 7 years
later, even if in the multivariate analysis
thisassociationdidnotretainasigniﬁcant
association (13). The present study adds
to the previous report because the fol-
low-up was extended at 15 years from
baseline and because fasting plasma
MCP-1/CCL2 was assessed in 156 men
also.
RESEARCH DESIGN AND
METHODS— The 363 individuals
who entered the study were selected from
a population survey carried out in 1990–
1991 in the Health District of Cremona
(Lombardy, Italy) that was performed to
determine the prevalence of diabetes in
Italy according to an oral glucose toler-
ance test (OGTT) and World Health Or-
ganization criteria (13). Fasting plasma
leptin, -tumor necrosis factor receptor 2
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trations were measured in patients with
type 2 diabetes (known to be affected or
previously undiagnosed) (n  99) and
patients with impaired glucose tolerance
(IGT) (n  77) for whom an aliquot of
frozen plasma sample was available,
which was stored at 80°C and had not
been previously thawed. From the above-
described population, 187 individuals
with normal glucose tolerance (NGT)
were randomly selected to be comparable
to the group of patients with type 2 dia-
betes and IGT in terms of age and anthro-
pometric parameters. Past medical
history and clinical data of subjects were
collected through a standard protocol
conducted by trained interviewers. A ve-
nous blood sample was collected after a
12-hovernightfast;thereafter,a75-goral
glucose monohydrate was given, and a
further venipuncture was performed 2 h
later. Anthropometric measures were ob-
tained by the same trained individual us-
ing the same instruments for all subjects.
Heartrateandsystolicanddiastolicblood
pressures were taken twice, at the begin-
ning and at the end of the visit, in the
sitting position and after at least a 10-min
rest using a full automatic noninvasive
sphygmomanometer. The lowest ﬁgure
was considered. Further details concern-
ingthestudyprotocolhavebeenreported
previously (14). Fifteen years later, vital
status and time of death were ascertained
through Regional Health Registry ﬁles
and causes of death were classiﬁed using
the ICD-8 and ICD-9 codes 401–448
(CVD), 410–414 (coronary heart disease),
and 430–438 (stroke). The protocol was
approved by the Ethics Committee of the
Istituto Scientiﬁco H San Raffaele.
Deﬁnition of diabetes, IGT, and
metabolic syndrome
Diabetes was deﬁned at that time accord-
ing to previously known diabetes status
(patients taking oral hypoglycemic
agents) or according to the results of the
OGTT and on the basis of World Health
Organization criteria (basal plasma glu-
cose 7.8 or 11.1 mmol/l after a 2-h
oral glucose load). Patients with known
diabetes did not undergo the OGTT. IGT
wasdeﬁnedasbasalplasmaglucose7.8
mmol/l and plasma glucose 7.8 but
11 mmol/l after a 2-h oral glucose
load. Metabolic syndrome was deﬁned
according to the deﬁnition of the Na-
tional Cholesterol Education Program
Adult Treatment Program III.
Analytical determinations
Blood and serum and plasma substrates
were assessed as described previously
(13). Blood was collected into tubes with
glycolytic inhibitor, and the glucose con-
centration was measured within 3–4 h in
the central laboratory through the GOD-
PAP glucose oxidase method (Boehringer
Mannheim, Milan, Italy) with a Hitachi
705autoanalyzer.Atthesametimeﬁbrin-
ogen, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), -glu-
tamyl transferase (GGT), and alkaline
phosphatase (ALP) were also determined.
An additional 20 ml of fasting blood was
immediately centrifuged, and plasma was
obtained for the assessment in the central
laboratory of insulin, triglycerides, and
total and HDL cholesterol. The plasma
human MCP-1/CCL2 concentration was
measuredin2001usinganoncommercial
sandwich enzyme-linked immunosor-
bent assay as described previously (15);
the enzyme-linked immunosorbent assay
for MCP-1/CCL2 is speciﬁc for human
MCP-1 and did not detect the closely re-
lated human chemokines MCP-2 and
MCP-3 (16). Leptin concentration was
determined as described previously (13)
by a radioimmunoassay with a human
kit (Linco Research, St. Charles, MO).
Intra-assay and interassay coefﬁcients of
variation (CVs) were 1.5 and 1.9%, re-
spectively. Insulin was determined by a
radioimmunoassay kit (intra-assay and
interassay CVs were 6.0 and 5.3%, re-
spectively) (Technogenetics, Medgenics,
Brussels, Belgium). -TNF-R2 was mea-
sured with an enzyme immunoassay fol-
lowing the manufacturer’s (Immunotech
Beckman Coulter, Marseille, France) rec-
ommendations as described previously
(13). Total cholesterol and triglycerides
were measured by enzymatic methods
(Boehringer Mannheim, Mannheim, Ger-
many) with the CIBA Corning 550 Ex-
press Autoanalyzer. The HDL fraction
was separated from plasma by precipita-
tionwithpolyethyleneglycolusingaCol-
ortest kit (Roche, Basel, Switzerland).
High-sensitivity C-reactive protein
In 2004, C-reactive protein (CRP) levels
(N high-sensitivity CRP assay; Dade-
Behring, Marburg, Germany) were mea-
sured in a subgroup of older individuals
(65 years old; n  447) within the en-
tirepopulationoftheCremonaStudyand
were reported in another article (17).
With respect to that assessment, we have
data for 113 subjects in whom MCP-1/
CCL2 and high-sensitivity CRP (hs-CRP)
were simultaneously available.
Calculation
BMIwascalculatedasweightinkilograms
divided by the square of height in meters.
Insulinsensitivitywasestimatedusingthe
quantitative insulin sensitivity check in-
dex(QUICKI)obtainedfromfastingbase-
linedeterminations(18)andcalculatedas
the logarithm and the reciprocal of the
insulin-glucose product:
QUICKI  1/[log(I0)  log (G0)]
Alcohol consumption was calculated as
units of alcohol (glass of wine  20 units,
glass of aperitif  30 units, and glass of
liquor  80 units).
Statistical analysis
Analyses were performed using SAS soft-
ware.Concentrationsarepresentedasav-
erages  SD unless otherwise stated.
ANOVA and 	
2 analysis were used for
comparison between groups, and the
Bonferroni adjustment was used for post
hoc comparisons. Because of the skewed
distribution of serum leptin, insulin, trig-
lycerides, ﬁbrinogen, glucose, AST, ALT,
GGT, and ALP, log-transformed values
were used in the analysis. Pearson corre-
lation analysis was used for correlations.
The association of the risk factors with
CVD mortality after the 15-year observa-
tional period was estimated by the Cox
univariate proportional hazards model.
Hazard ratios (HRs) and 95% CIs are pre-
sented. A multivariate Cox proportional
model (stepwise), including parameters
with P  0.1 on univariate analysis, was
used to investigate the independent asso-
ciation of the risk factors with CVD
mortality.
RESULTS
Anthropometric and laboratory
characteristics of study subjects
Subjects with type 2 diabetes and IGT
were slightly older, but post hoc testing
did not reach statistical difference among
groups (Table 1). BMI and waist circum-
ference were not statistically different
among groups. Waist-to-thigh ratio was
signiﬁcantlyincreasedinindividualswith
type 2 diabetes with respect to that in in-
dividuals with NGT; this feature was
more evident in women (P  0.0001)
than in men (P  0.274). The prevalence
of smokers was not different in the three
groups. Systolic and diastolic blood pres-
MCP-1/CCL2 and CVD mortality
2106 DIABETES CARE, VOLUME 32, NUMBER 11, NOVEMBER 2009 care.diabetesjournals.orgsures showed an increasing trend accord-
ing to glucose tolerance. Systolic (P 
0.008) and diastolic (P  0.087) blood
pressures were higher in women with
type 2 diabetes with respect to those in
women with NGT, whereas this feature
was less evident in men (P  0.172 and
P  0.130 for systolic and diastolic pres-
sure, respectively). As expected, fasting
and 2-h serum glucose concentrations
were increased in patients with type 2 di-
abetes and IGT in comparison with those
in subjects with NGT. Total cholesterol
and LDL cholesterol were not different in
the groups. However, HDL cholesterol
and triglycerides differed signiﬁcantly in
patients with type 2 diabetes, which
showed unfavorable alterations of the
lipid proﬁle. The lipid proﬁles of subjects
with IGT, on the contrary, were not dif-
ferent from those of individuals with
NGT. Serum ALT, AST, GGT, ALP, and
ﬁbrinogen were not different in any
groups. Patients with type 2 diabetes and
IGT were characterized by fasting hyper-
insulinemia and by insulin resistance ex-
pressed as a signiﬁcantly lower QUICKI
value. Serum leptin were not different in
the study groups when leptin concentra-
tion was normalized to the BMI units.
Cross-sectional analysis of baseline
MCP-1/CCL2
The plasma MCP-1/CCL2 concentration
was increased in type 2 diabetic women
but not in those with IGT with respect to
those with NGT (Table 1). MCP-1/CCL2
was not associated with any anthropo-
metric parameters but showed a signiﬁ-
cant association with biochemical
markersofatheroscleroticdisease.Infact,
MCP-1/CCL2 was associated with fasting
(R  0.15; P  0.007) and 2-h plasma
glucose after the glucose challenge (R 
0.14; P  0.04), HDL cholesterol (R 
0.21; P  0.0003), and plasma triglyc-
erides (R  0.15; P  0.01). These pa-
rametersaretypicalmarkersoftheinsulin
resistance syndrome; conﬁrming this ob-
servation, QUICKI was also found to be
signiﬁcantly associated (R  0.19; P 
0.009). In addition, MCP-1/CCL2
showed a signiﬁcant association with
-TNF-R2 (R  0.14; P  0.01) but no
association with leptin. Even if MCP-1/
CCL2 was not signiﬁcantly associated
with BMI, we tested whether the above-
described association of MCP-1/CCL2
was independent of BMI. The results of
this analysis demonstrated that all the
correlations remained signiﬁcant regard-
less of the parameter of body adiposity.
Univariate analysis after the 15-year
observational period
After 15 years, among the 363 subjects,
82 deaths occurred due to CVD (22.6%)
(Table 2). The CVD mortality rate was
30% in patients with type 2 diabetes (30
of 99), 19.5% in individuals with IGT (15
of 77), and 19.8% in individuals with
NGT (37 of 187). In univariate analysis,
age (HR 1.127 [95% CI 1.098–1.157];
P  0.0001) was associated with CVD
mortality, and female sex was less prone
to be associated (0.429 [0.275–0.671];
P  0.0002). Age- and sex-adjusted uni-
variate analysis showed that fasting
plasma glucose concentration, MCP-1/
CCL2, ﬁbrinogen, cigarette smoking, and
diabetes were signiﬁcantly associated
with CVD mortality (Table 2). In addi-
tion, fasting insulin showed a trend to be
associated with CVD mortality (P 
0.064).Whentheanalysiswasperformed
separately by sex, age, fasting plasma glu-
cose,andMCP-1/CCL2weresigniﬁcantly
associated in both men and women,
whereasfastingplasmainsulinandsmok-
ing were signiﬁcantly associated with
CVD mortality only in men and serum
ﬁbrinogen was signiﬁcantly associated
with CVD mortality only in women.
Multivariate analysis after the 15-
year observational period
Multivariate analysis was performed us-
ing only variables signiﬁcant at P  0.1 in
univariateanalysis.Theanalysisintheen-
tirepopulation(Table3)showedthatage,
sex, fasting glucose, MCP-1/CCL2, and
smoking were independent predictive
variables of CVD mortality (Table 3).
hs-CRP and MCP-1/CCL2
For hs-CRP, data on MCP-1/CCL2 and
hs-CRP were simultaneously available for
only 113 subjects. These subjects were
older (71  4 years) than those reported
in the present article, and the number of
cardiovascular events was 46. No correla-
tion between plasma MCP-1/CCL2 and
Table 1—Anthropometric and laboratory parameters of study subjects
Type 2 diabetes IGT NGT
n (female/male) 99 (53/46) 77 (42/35) 187 (112/75)
Anthropometric parameters
Age (years) 63  11 63  12 60  13
Body weight (kg) 77  17 71  16 77  17
Height (cm) 161  9 158  10 160  10
BMI (kg/m
2) 30.0  6.3 28.3  5.0 29.9  6.0
Waist (cm) 98  14 94  14 95  15
Waist-to-thigh ratio 1.84  0.19* 1.81  0.23 1.74  0.24
Smoking habit n (%) 20 (20%) 15 (19%) 46 (25%)
Alcohol consumption (alcohol units) 3  11 2  10 2  8
Systolic blood pressure (mmHg) 161  24* 155  20 151  21
Diastolic blood pressure (mmHg) 86  14* 83  13 82  12
Biochemical laboratory parameters
Glucose (mmol/l) 7.27  1.67*† 5.55  0.83* 5.11  0.50
2-h glucose (mmol/l) 12.71  3.83*† 9.10  0.83* 4.83  1.22
Cholesterol (mmol/l) 6.00  1.03 6.03  1.01 6.15  1.24
HDL cholesterol (mmol/l) 1.14  0.34*† 1.34  0.49 1.32  0.39
Triglycerides (mmol/l) 1.63  0.92*† 1.37  0.57 1.38  0.51
ALT (units/liter) 27  10 28  11 26  8
AST (units/liter) 24  11 23  15 22  15
GGT (units/liter) 36  30 35  31 27  30
ALP (units/liter) 174  51 176  45 172  45
Fibrinogen (mg/dl) 286  79 297  66 275  61
Hormones
Insulin (pmol/l) 131  108*† 103  52 95  41
Leptin (ng/ml) 10.7  4.5 10.0  5.8 10.4  5.0
MCP-1/CCL2 (pg/ml) 224  275* 195  171 159  113
Insulin sensitivity
QUICKI 0.127  0.014*† 0.136  0.014 0.138  0.011
DataaremeansSDorn(%).Leptin,insulin,triglycerides,glucose,AST,ALT,GGT,andALPareexpressed
asgeometricmeansSD.SubjectswithapreviouslyproveddiagnosisofdiabetesdidnotundergoanOGTT.
*P  0.05 vs. NGT. †P  0.05 vs. IGT ANOVA and Bonferroni post hoc analysis.
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was detected. In univariate analysis hs-
CRP was not related to CVD (HR 1.029
[95%CI0.984–1.076];P0.22),andin
this smaller cohort MCP-1/CCL2 but not
hs-CRP (1.030 [0.986–1.077]; P  0.19)
showed a trend to be signiﬁcantly associ-
ated with CVD mortality in age- and sex-
adjusted multivariate analysis (1.001
[1.000–1.002]; P  0.0593).
CONCLUSIONS — In the present
study, we have shown that in middle-
aged overweight/obese individuals, the
fasting plasma MCP-1/CCL2 concentra-
tionwasrelatedtobiochemicalriskmark-
ers of atherosclerosis and that this
concentration was higher in individuals
with type 2 diabetes and IGT with respect
to that in nondiabetic patients. Most im-
portantly, when CVD mortality was as-
sessed retrospectively 15 years after the
baseline assessment, we report that MCP-
1/CCL2 was independently associated
with CVD mortality.
Pathophysiological implications
Ourresultsshowedthatdiabetesmaybea
determinant of the circulating levels of
MCP-1/CCL2. In fact, at baseline, MCP-
1/CCL2 was associated with biochemical
markers of the metabolic syndrome such
as serum triglycerides, HDL cholesterol,
and surrogate markers of insulin sensitiv-
ity (QUICKI). With respect to insulin re-
sistance, because obese insulin-resistant
subjects are in a proinﬂammatory state
with an increase in intranuclear nuclear
factor-
B binding activity (19) and be-
cause insulin was shown to suppress the
MCP-1/CCL2 plasma concentration in
vivo (20), insulin resistance itself may ex-
plain why MCP-1/CCL2 was increased in
our patients. In addition, the higher
amountofplasmaMCP-1/CCL2observed
in individuals with type 2 diabetes was
correlated with both fasting and 2-h
plasma glucose after the glucose chal-
lenge,suggestingthathyperglycemiamay
have an independent contribution in ex-
plaining the circulating levels of MCP-1/
CCL2. This ﬁnding was not unexpected
because in vitro, advanced glycation end-
products, a high glucose concentration,
glycated albumin, and glycoxidized LDL
enhanced MCP-1/CCL2 expression in
human endothelial cells (21). More im-
portantly, the results support the hypoth-
esis that MCP-1/CCL2 may be involved
directly in the pathogenesis of atheroscle-
rosis in humans because its baseline se-
rum concentration was independently
associated with CVD mortality assessed
15 years after the baseline determination
of its fasting plasma concentration. There
are many data in the literature that sup-
port a role of MCP-1/CCL2 in the patho-
genesis of both the initiation and
progression of atherosclerosis. MCP-1/
CCL2 was found to be highly expressed
withinatheroscleroticlesions(22),andits
role in atherogenesis is consistent with in
vitroandinvivostudiesinanimalmodels
(23). In humans, elevated MCP-1/CCL2
serum levels were found to be increased
not only in individuals with diabetes but
also in subjects at risk because of other
risk factors for atherosclerosis, such as
age, hypertension, hypercholesterolemia,
renal failure, and vascular disease or in
individuals with overt coronary artery
disease as outlined in the INTRODUCTION.
Recently, a genetic variation in the MCP-
1/CCL2genewasassociatedwithahigher
serum concentration of the chemokine
and a higher prevalence of myocardial in-
farction (24).
Clinical implications
Theresultsofthepresentstudyarepoten-
tially clinically important. With regard to
the inﬂammatory hypothesis of athero-
sclerosis, these data suggest that elevated
MCP-1/CCL2 levels, serving as a direct
markerofinﬂammatoryactivity,mayalso
be a biomarker of the risk of CVD. Hold-
ing this view and taking into account the
fact that the fasting MCP-1/CCL2 level
predicted CVD mortality when assessed
15yearslater,wesuggestthatthischemo-
kine may be an early independent predic-
tor of atherosclerosis and an early
biomarker of its natural development in
the history of an at-risk individual. Inter-
estingly, within our population the MCP-
1/CCL2 plasma concentration was linked
more strongly with CVD than the post-
challenge plasma glucose concentration,
metabolic syndrome, and serum circulat-
ing lipids (Table 2). Another clinical im-
plication is that because treatment of
several components of the insulin resis-
tance syndrome (adiposity, dyslipidemia,
Table 2—Age- and sex-adjusted risk ratio associated with 15 years cardiovascular mortality
by univariate analysis
Variable HR (95% CI) P
BMI 1.037 (0.992–1.083) 0.109
LDL cholesterol 0.999 (0.993–1.005) 0.769
HDL cholesterol 0.994 (0.98–1.009) 0.448
Triglycerides 1.001 (0.997–1.004) 0.723
Fasting glucose 1.010 (1.004–1.016) 0.0015
2-h glucose 1.002 (0.997–1.007) 0.367
Fasting insulin 1.011 (0.999–1.023) 0.064
Systolic blood pressure 1.005 (0.995–1.015) 0.296
Diastolic blood pressure 1.004 (0.987–1.022) 0.642
Leptin 0.998 (0.972–1.026) 0.910
-TNF-R2 1.000 (1.000–1.000) 0.987
MCP-1/CCL2 1.001 (1.000–1.002) 0.019
Fibrinogen 1.003 (1.000–1.006) 0.021
Smoking 2.383 (1.211–4.691) 0.012
Metabolic syndrome 1.117 (0.701–1.779) 0.641
Diabetes 1.716 (1.092–2.697) 0.019
Data are HR (95% CI).
Table 3—Cox proportional hazards model of the predictors of 15 years CVD mortality by
multivariate analysis
Variable HR (95% CI) P
Age 1.153 (1.114–1.193) 0.0001
Sex 0.434 (0.259–0.728) 0.0006
Fasting glucose 1.009 (1.001–1.016) 0.0253
MCP-1/CCL2 1.001 (1.000–1.002) 0.0089
Cigarette smoking 2.432 (1.110–5.328) 0.035
Data are HR (95% CI). Only variables signiﬁcant at P  0.1 at univariate analysis were tested in the models.
Only variables that remained signiﬁcantly associated are shown.
MCP-1/CCL2 and CVD mortality
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in preventing cardiovascular disease, if
subclinical inﬂammation is indeed an-
other facet of the insulin resistance syn-
drome, anti-inﬂammatory treatment may
also be beneﬁcial. A recent randomized
clinical trial tested the administration of
20mg/dayrosuvastatininnondiabeticin-
dividuals with anthropometric features
similar to those of the subjects in our
study (age, sex, and BMI) who had LDL
cholesterol levels in the normal range but
higher circulating hs-CRP levels. In this
study, a 44% reduction of major cardio-
vascular events along with a signiﬁcant
reductionofhs-CRPcirculatinglevelswas
reported (25), suggesting that the effects
of this statin may, at least partly, be me-
diated through anti-inﬂammatory prop-
erties. In addition, it is known that
pharmacological treatment with hy-
droxymethylglutaryl-CoA reductase in-
hibitors may lower MCP-1/CCL2 levels
(9). Thus, elevated MCP-1/CCL2 levels
couldidentifypatientsmorelikelytoben-
eﬁt from aggressive statin treatment, al-
though we must emphasize that whether
treatments to reduce circulating levels of
MCP-1/CCL2areeffectiveinreducingthe
onset of CVD is yet to be determined.
Based also on our results, the hypothesis
that the development of pharmacological
tools able to target anti-inﬂammatory
pathways may be a potential approach to
reduce rates of vascular events may be
true. More potent prospective studies are
clearly needed to address these issues.
Study limitations and strengths
The population in which MCP-1/CCL2
plasmaconcentrationswereobtainedwas
small, and larger studies are needed to
conﬁrm our results. Conversely, our ob-
servational period was 15 years, and we
had a high number of events (82 CVD
deaths in 363 individuals) relative to the
entire population. An additional limita-
tion was that the distribution of MCP-1/
CCL2 plasma concentrations in the
individualswithCVDmortalityandthose
without overlapped considerably, sug-
gesting that plasma MCP-1/CCL2 levels
alone will not be helpful in predicting
CVD mortality. Therefore, we are explor-
ing circulating levels of MCP-1/CCL2 as a
systemic surrogate, trying to test whether
these may be linked to a local event (ath-
erosclerosis). However, when MCP-1/
CCL2 is considered along with other
classic risk factors, it may eventually be
useful as a surrogate biomarker in pa-
tients with IGT and diabetes.
Another limitation of the study is that
we did not obtain serial plasma MCP-1/
CCL2 concentrations. The association we
report in the present work is between one
single assessment of the plasma chemo-
kine concentration and the CVD mortal-
ity assessed 15 years later, but we have no
data about the circulating levels of the
chemokine during the observational
period.
Finally,wetestedMCP-1/CCL2along
with a standard inﬂammatory marker
such as ﬁbrinogen because that biomar-
kerwasmeasuredin1990–1991.hs-CRP
is a more reliable marker, but, unfortu-
nately, we only had simultaneous avail-
ability of MCP-1/CCL2 and hs-CRP for
113 subjects. Even if MCP-1/CCL2 re-
mained associated with CVD mortality in
this subset of individuals, suggesting an
independent role of MCP-1/CCL2, a rig-
orous comparison remains to be done.
In summary, in the present study, we
reportthatinmiddle-agedindividualsthe
plasma MCP-1/CCL2 concentration was
related to biochemical risk markers of
atherosclerosis and, in particular, to both
fasting and post-OGTT plasma glucose
concentrations. In the multivariate analy-
sis MCP-1/CCL2 was associated with in-
creased CVD mortality assessed 15 years
later.
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